News MSD records one hit, one miss with TL1A drug tulisokibart MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.
News MSD's TL1A drug tulisokibart delivers in pivotal IBD trial MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.
News MSD advances on a broad front with TL1A drug tulisokibart MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.